SCHEMBL5329685

SCHEMBL5329685

Cn1c(=O)[nH]c2ccc(Cl)nc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.58
GAA P10253 1/20 0.58
LMNA P02545 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
PABPC1 P11940 1/20 0.53
PDE3B Q13370 3/20 0.47
PDE3A Q14432 3/20 0.47
IDH1 O75874 1/20 0.41
PGR P06401 1/20 0.41
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
ADORA1 P30542 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
DAO P14920 2/20 0.38
CYP3A4 P08684 1/20 0.38
MAPK1 P28482 1/20 0.38
PMP22 Q01453 1/20 0.38
ATM Q13315 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31217710 1.00 KDM4E (0.58) KDM4EGAALMNAMEN1KMT2A
SCHEMBL2268013 0.80 KDM4E (0.59) KDM4EGAALMNAMEN1KMT2A
SCHEMBL14609834 0.79 KDM4E (0.58) KDM4EGAALMNAMEN1KMT2A
SCHEMBL25351889 0.78 PGR (0.47) KDM4EGAAPGR
SCHEMBL2272021 0.76 KDM4E (0.55) KDM4EGAALMNAMEN1KMT2A
SCHEMBL1600147 0.74 ALDH1A1 (0.44) KDM4EGAALMNAMEN1KMT2A
SCHEMBL2265319 0.74 LMNA (0.60) KDM4EGAALMNAMEN1KMT2A
SCHEMBL29864436 0.74 LMNA (0.60) KDM4EGAALMNAMEN1KMT2A
SCHEMBL25422258 0.73 HCAR1 (0.51) PGR
SCHEMBL11223721 0.72 KDM4E (0.51) KDM4EGAALMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4559906-A1 HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN Astellas Pharma Inc. (JP) 2025-05-28 EP disclosed
US-20250145631-A1 HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN ASTELLAS PHARMA INC. (JP) 2025-05-08 US disclosed
WO-2024019103-A1 HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN アステラス製薬株式会社 2024-01-25 WO disclosed
EP-2721029-B1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
EP-2721029-B1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME (US) 2018-07-18 EP disclosed
US-9315518-B2 Imidazopyridin-2-one derivatives MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-9315518-B2 Imidazopyridin-2-one derivatives MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-9315518-B2 Imidazopyridin-2-one derivatives MERCK SHARP & DOHME CORP. (US) 2016-04-19 US disclosed
US-20140350002-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-11-27 US disclosed
US-20140350002-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2014-11-27 US disclosed
US-8765784-B2 Positive allosteric modulators of MGLUR2 MERCK SHARP & DOHME CORP. (US) 2014-07-01 US disclosed
US-8765784-B2 Positive allosteric modulators of MGLUR2 MERCK SHARP & DOHME CORP. (US) 2014-07-01 US disclosed
US-20130210768-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
US-20130210768-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
US-20130210768-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME LLC 2013-08-15 US disclosed
WO-2012174199-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2012-12-20 WO disclosed
WO-2011156245-A2 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 MERCK SHARP & DOHME CORP. (US) 2011-12-15 WO disclosed
WO-2011034741-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2011-03-24 WO disclosed
WO-2007015877-A2 INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS KALYPSYS, INC. (US) 2007-02-08 WO disclosed
WO-2007015877-A2 INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS KALYPSYS, INC. (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145631-A1 HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN KRAS, NRAS, HRAS KDM4E 3766/4885GAA 1801/4885LMNA 4165/4885
US-20130210768-A1 POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 GRM2, GRM1, GRIA2 KDM4E 1691/4885GAA 3681/4885LMNA 4840/4885
US-20140350002-A1 IMIDAZOPYRIDIN-2-ONE DERIVATIVES GRM2, GRIN2C, GRM1 KDM4E 3450/4885GAA 2592/4885LMNA 4764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.